Sparian Biosciences, a New York-based for-profit company, has received a USD 3.1 million NIDA UG3 grant to advance SBS-147, an oral non-opioid analgesic, into Phase I and Phase IIa clinical trials — a meaningful signal that federal funders are willing to back early commercial-stage development of alternatives to opioids for pain management.
SBS-147 targets the arylepoxamide receptor (AEAr), a non-opioid pathway with preclinical activity across nociceptive, neuropathic, and inflammatory pain models. The compound is an oral prodrug derivative of SBS-1000, an intravenous formulation that completed a Phase I trial in healthy volunteers and demonstrated safety, tolerability, and a signal of analgesic activity in the Cold Pressor Test without evidence of opioid receptor engagement — a key differentiator given that pupil constriction, a pharmacodynamic marker of opioid activity, was absent. The grant will fund a Phase I single- and multiple-ascending dose study to characterize the safety and pharmacokinetics of the oral formulation, followed by a Phase IIa dental pain study as a proof-of-concept efficacy endpoint. Principal investigators are Judy Ashworth and Anna Pasternak.
The non-opioid analgesic field has attracted substantial industry and regulatory attention, with approved agents including suzetrigine (Journavx), a Nav1.8 sodium channel blocker from Vertex Pharmaceuticals, and tanezumab, an anti-NGF antibody that faced a protracted regulatory path. SBS-147's AEAr mechanism is distinct from both sodium channel and nerve growth factor approaches, and the absence of physical dependence or respiratory depression in preclinical models positions it as a candidate for both acute and chronic pain indications where opioid risk is a clinical concern.